Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
Neurological diseases, which consist of acute injuries and chronic neurodegeneration, are the leading causes of human death and disability. However, the pathophysiology of these diseases have not been fully elucidated, and effective treatments are still lacking. Astaxanthin, a member of the xanthophyll group, is a red-orange carotenoid with unique cell membrane actions and diverse biological activities. More importantly, there is evidence demonstrating that astaxanthin confers neuroprotective effects in experimental models of acute injuries, chronic neurodegenerative disorders, and neurological diseases. The beneficial effects of astaxanthin are linked to its oxidative, anti-inflammatory, and anti-apoptotic characteristics. In this review, we will focus on the neuroprotective properties of astaxanthin and explore the underlying mechanisms in the setting of neurological diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 1×
“Disturbance of the equilibrium status of pro-oxidant/anti-oxidant reactions in cells can lead to oxidative stress, which causes generation of reactive oxygen species (ROS) and free radicals [43].”
BackgroundApoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853 · cited 1×
“Apoptosis is a highly sophisticated energy-dependent process of programmed cell death [86].”
BackgroundNF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182 · cited 1×
“Under normal conditions NF-κB, a heterodimer composed of p50 and p65 subunits, interacts with inhibitor of NF-κB (IκB) and remains inactive in the cytosol [69].”
BackgroundSuperoxide radical and superoxide dismutases
Fridovich, I. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.000525 · Cited by 3,455 · cited 2×
“The O2− radical can oxidize the [4Fe-4S] clusters of dehydratases, such as aconitase, causing inactivation and release of Fe2+ [46,47].”
BackgroundAdams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,171
Ambati, R., Phang, S.-M., Ravi, S., & Aswathanarayana, R. (2014) · Marine Drugs · doi:10.3390/md12010128 · Cited by 1,974 · cited 3×
“xanthophylls, astaxanthin has two hydroxyl groups [13].”
BackgroundInfluentialHuntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743 · cited 1×
“Additionally, highly polymorphic CAG tri-nucleotide repeat expansions in exon-1 of the huntingtin gene encodes an abnormally long poly-glutamine repeat, which is associated with Huntington’s disease (HD)-related brain pathology [10].”
BackgroundMolecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663 · cited 1×
“, α-synuclein), and dysfunction of ubiquitin-proteasome system represents the principal molecular events that commonly underlie the pathogenesis of familial and sporadic forms of Parkinson’s disease (PD) [8,9].”
BackgroundGiasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & -Y. Lee, V. M. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,546 · cited 1×
“Oxidative stress is a key mediator in the pathology of neurological diseases [40–42].”
BackgroundHaematococcus astaxanthin: applications for human health and nutrition
Guerin, M., Huntley, M. E., & Olaizola, M. (2003) · Trends in Biotechnology · doi:10.1016/s0167-7799(03)00078-7 · Cited by 1,495 · cited 3×
“In addition, the United States Food and Drug Administration approved the use of astaxanthin as a dietary supplement in 1999 [25].”
Background
Cited by
Blunt, J. W., Copp, B. R., Keyzers, R. A., Munro, M. H. G., & Prinsep, M. R. (2017) · Natural Product Reports · doi:10.1039/c6np00124f · Cited by 465
Astaxanthin: A mechanistic review on its biological activities and health benefits
Fakhri, S., Abbaszadeh, F., Dargahi, L., & Jorjani, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.012 · Cited by 461
On the Neuroprotective Role of Astaxanthin: New Perspectives?
Galasso, C., Orefice, I., Pellone, P., Cirino, P., Miele, R., Ianora, A., Brunet, C., & Sansone, C. (2018) · Marine Drugs · doi:10.3390/md16080247 · Cited by 227
Food and High Value Products from Microalgae: Market Opportunities and Challenges
Rahman, K. M. (2020) · Microalgae Biotechnology for Food, Health and High Value Products · doi:10.1007/978-981-15-0169-2_1 · Cited by 115
Metadata
- Authors
- Wu, H., Niu, H., Shao, A., Wu, C., Dixon, B., Zhang, J., Yang, S., & Wang, Y.
- Venue
- Marine Drugs
- Publisher
- MDPI AG
- Published
- 2015-09-11
- Volume
- 13
- Issue
- 9
- Pages
- 5750-5766
- ISSN
- 1660-3397 (ISSN-L)
- OpenAlex
- W2155140532
- Cited by
- 199
- References
- 101
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.